P2, N=34, Completed, HonorHealth Research Institute | N=11 --> 34

P2, N=23, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Mar 2026 --> Nov 2026

P2, N=35, Not yet recruiting, City of Hope Medical Center

P2, N=140, Not yet recruiting, Institute of Oncology Ljubljana

The patient was subsequently referred for standard-of-care adjuvant chemoradiation, including external-beam radiation therapy with concurrent and adjuvant temozolomide, which represents the current recommended treatment approach for high-grade gliomas harboring H3K27M mutations...This unusual hemispheric H3K27M-mutant tumor morphologically mimicked an oligodendroglioma. We recommend routine H3K27M testing in IDH-wildtype hemispheric gliomas with ATRX loss.

This case highlights that recurrent CRAO in young patients should prompt investigation for underlying hematological disorders such as ET. Early diagnosis, appropriate cytoreductive and antiplatelet therapy, and long-term multidisciplinary follow-up are essential to prevent vision loss and life-threatening thrombotic complications.

P3, N=266, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2024 --> Dec 2029 | Trial primary completion date: Jul 2024 --> Dec 2026

Caprin-1 silencing enhances cisplatin sensitivity in CC by suppressing the YY1/HSP90α axis, accelerating IDH1 degradation, and activating ferroptosis.

These findings provide novel insights into the molecular mechanisms of Gn-Rh2 in enhancing chemotherapy sensitivity and suggest a promising therapeutic strategy for NSCLC.

In this study, we targeted PD-L1 using an siRNA and AXL using a blocker (R428) in OVACAR-3 and CaSki cells, ovarian and cervical cancer cell lines, respectively, in the following groups: Scramble-siRNA, PD-L1-siRNA, Scramble-siRNA in conjunction with R428, PD-L1-siRNA in conjunction with R428, R428 monotherapy and untreated controls. Cell viability was assessed by MTT assay after 48 hours of treatment, and cisplatin sensitization was evaluated in resistant OVACAR-3 cells...The results showed a significant decrease in cell proliferation, suppression of EMT-regulating genes, reduction of stemness in cancer cells, increased apoptosis and disruption of the cell cycle in the studied cell lines. These findings suggest that simultaneous blockade of PD-L1 and AXL could serve as a novel tumor-suppressive strategy, especially for cancer patients resistant to ICBs.

Andrographolide overcomes intrinsic Gem resistance in ICC, potentially through modulation of the RRM2/JAK/STAT3 axis. This combination therapy represents a promising strategy for treating chemoresistant intrahepatic cholangiocarcinoma.

In cell assays, C-1305 shows low-micromolar cytotoxicity across multiple cancer cell lines while being markedly less toxic to normal cells, outperforming cisplatin in potency. These results reposition C-1305 from a putative GGG intercalator to a G4-targeting pharmacophore and outline a route to side-chain engineering for improved G4 selectivity.